Oligometastasis of Gastric Cancer: A Review

Yasufuku, Itaru; Tsuchiya, Hiroshi; Fujibayashi, Seito; Okumura, Naoki; Sengoku, Yuki; Fukada, Masahiro; Asai, Ryuichi; Sato, Yuta; Tajima, Jesse Yu; Kiyama, Shigeru; Kato, Takazumi; Tanaka, Yoshihiro; Murase, Katsutoshi; Matsuhashi, Nobuhisa

doi:10.3390/cancers16030673

Cited by 4 publications

(3 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the AIO-FLOT3 (Arbeitsgemeinschaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial revealed a good prognosis by prospectively assessing the effectiveness of multimodal treatments for GC patients with oligometastases, such as surgical excision of primary and metastatic lesions in conjunction with chemotherapy [21].…”

Section: Prognosismentioning

confidence: 99%

Prognosis and Treatment of Gastric Cancer: A 2024 Update

Burz,

Pop,

Silaghi

et al. 2024

Cancers

View full text Add to dashboard Cite

Due to the high death rate associated with gastric cancer, a great deal of research has been conducted on this disease. The goal of this paper was to start a trimestral review of 2024 for the year that had just started. The scientific literature from 1 January 2024 was chosen with consideration of the the guidelines of the European Society of Medical Oncology (ESMO), which are updated with new findings but not systematically reviewed annually. We used the search term “gastric cancer” to find the most current publications in the PubMed database related to the prognosis and treatment of gastric cancer. As previously said, the only articles that satisfied the inclusion criteria were those from 2024. Articles with case reports were eliminated since they had nothing to do with our research. The treatment of gastric cancer is the focus of the majority of articles from 2024. The primary research axes include surgery and immunonutrition, immunotherapy and Helicobacter pylori, and therapeutic targets. Patients with GC may experience less psychological, social, and financial hardship if the recently identified markers discovered in circulation are better assessed and validated. This could be achieved by either including the markers in an artificial intelligence-based diagnostic score or by using them in conjunction with traditional diagnostic methods. Due to the rising death rate associated with GC, funding for research into diagnosis, prognosis, therapy, and therapeutic targets is essential.

show abstract

Section: Prognosismentioning

confidence: 99%

Prognosis and Treatment of Gastric Cancer: A 2024 Update

Burz,

Pop,

Silaghi

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Distant metastasis poses a major challenge to the long-term survival of patients with gastric cancer (GC) ( 1 , 2 ). Notably, ovarian metastasis (OM), also known as Krukenberg tumor, is one of the most common patterns of metastasis, especially in young, premenopausal female population ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

Significance of dysregulated M2 macrophage and ESR2 in the ovarian metastasis of gastric cancer

Gao,

Zhao,

Pan

et al. 2024

Transl Cancer Res

View full text Add to dashboard Cite

Background Prognosis of gastric cancer (GC) patients with ovarian metastasis (OM) remains poor. We hereby characterized the role of tumor immune microenvironment (TIME) and identified potential key regulators in the OM with the aim of understanding its molecular basis to develop novel therapeutic targets. Methods Transcriptomic analyses of paired primary and ovarian metastatic lesions of seven GC patients from Fudan University Shanghai Cancer Center uncovered and functionally annotated their differentially expressed genes (DEGs). CIBERSORT analysis revealed differential TIME between primary GCs and OMs, which was further validated by multiplex immunofluorescence (mIF). Unique overexpression of candidate regulator in OMs was validated by an immunohistochemical (IHC) staining-based cohort study and in vitro cell growth, migration and invasion assays were conducted to characterize its function in GC progression. Results Functional enrichment analyses of DEGs between GCs and matched OMs revealed multiple significantly dysregulated immune-related and cancer-related pathways. Distinctive subsets of immune cells, especially M2 macrophage, were selectively enriched in metastatic lesions. mIF-based quantification further validated the overexpression of CD68 + CD206 + M2 macrophage in the OMs. Estrogen receptor 2 ( ESR2 ), which encodes estrogen receptor β (ERβ), was not only potentially correlated with M2 macrophage but also overexpressed in the OM of GC. ESR2 was up-regulated in cancerous tissue and its high expression correlated with younger age, more advanced lymph node metastasis and pathological stage, as well as a worse patient survival. IHC staining of ERβ in the cohort of paired primary and metastatic GCs validated its selective overexpression in OMs. Small-interfering RNAs (siRNAs)-induced knockdown of ESR2 significantly inhibited the invasion and migration of both AGS and HGC-27 GC cell lines. Conclusions Comparative RNA-sequencing analysis revealed the dysregulated TIME, M2 macrophage in particular, between primary GC and OM. ESR2 potentially correlated with M2 macrophage and played pro-oncogenic roles in GC progression and metastasis.

show abstract

“…The prognosis for gastric cancer with distant metastasis is poor [2], and chemotherapy with anticancer or molecular-targeted drugs is considered the mainstay of treatment [3,4]. However, recent developments in chemotherapy have had a remarkable impact on treatment strategies for unresectable metastatic gastric cancer [5].…”

Section: Introductionmentioning

confidence: 99%

Minimally Invasive Conversion Surgery for Unresectable Gastric Cancer with Splenic Metastasis and Splenic Vein Tumor Thrombus: A Case Report

Tanioka,

Kuwahara,

Sakai

et al. 2024

Current Oncology

View full text Add to dashboard Cite

While the importance of conversion surgery has increased with the development of systemic chemotherapy for gastric cancer (GC), reports of conversion surgery for patients with GC with distant metastasis and tumor thrombus are extremely scarce, and a definitive surgical strategy has yet to be established. Herein, we report a 67-year-old man with left abdominal pain referred to our hospital following a diagnosis of unresectable GC. Esophagogastroduodenoscopy and contrast-enhanced abdominal computed tomography (CT) revealed advanced GC with splenic metastasis. A splenic vein tumor thrombus (SVTT) and a continuous thrombus to the main trunk of the portal vein were detected. The patient was treated with anticoagulation therapy and systemic chemotherapy comprising S-1 and oxaliplatin. One year following chemotherapy initiation, a CT scan revealed progressive disease (PD); therefore, the chemotherapy regimen was switched to ramucirumab with paclitaxel. After 10 courses of chemotherapy resulting in primary tumor and SVTT shrinkage, the patient underwent laparoscopic total gastrectomy (LTG) and distal pancreaticosplenectomy (DPS). He was discharged without complications and remained alive 6 months postoperatively without recurrence. In summary, the wait-and-see approach was effective in a patient with GC with splenic metastasis and SVTT, ultimately leading to an R0 resection performed via LTG and DPS.

show abstract

Oligometastasis of Gastric Cancer: A Review

Cited by 4 publications

References 52 publications

Prognosis and Treatment of Gastric Cancer: A 2024 Update

Prognosis and Treatment of Gastric Cancer: A 2024 Update

Significance of dysregulated M2 macrophage and ESR2 in the ovarian metastasis of gastric cancer

Minimally Invasive Conversion Surgery for Unresectable Gastric Cancer with Splenic Metastasis and Splenic Vein Tumor Thrombus: A Case Report

Contact Info

Product

Resources

About